Serum Surfactant Protein D and Haptoglobin as Potential Biomarkers for Inflammatory Airway Disease in Horses by Bullone, M. et al.
Serum Surfactant Protein D and Haptoglobin as Potential
Biomarkers for Inflammatory Airway Disease in Horses
M. Bullone*, M. de Lagarde*, A. Vargas, and J.-P. Lavoie
Background: The identification of serum biomarkers of lung inflammation would facilitate the diagnosis of inflammatory
airway disease (IAD) in horses.
Hypothesis: Horses with IAD have higher serum concentrations of markers of inflammation compared to controls.
Animals: Twelve horses with IAD and 10 control horses.
Methods: This was a prospective case–control study. Blood and BALF were collected from horses with IAD and controls.
Serum concentration of surfactant protein D (SP-D), haptoglobin, serum amyloid A (SAA) and of the soluble form of trig-
gering receptor expressed on myeloid cells 1 (sTREM-1) was measured using commercial ELISA tests.
Results: Horses with IAD had higher serum concentration (log-transformed values) of SP-D (mean  SD: 1.773  0.51),
haptoglobin (6.657  0.202) and SAA (0.128  0.396) compared to controls (0.942  0.226, 6.38  0.22, 0.398  0.319,
respectively; P < .01 for all). Furthermore, the concentrations of SP-D and haptoglobin combined allowed differentiating the
2 groups (IAD: 8.43  0.564, controls: 7.322  0.249, P < .0001) with a sensitivity and specificity of 100% when a cut-off of
7.70 (log value) was employed.
Conclusions and Clinical Importance: Surfactant protein D and haptoglobin serum concentrations could be a diagnostic aid
in IAD. Further studies are necessary to establish the specificity of our findings before they can be applied in everyday practice.
Key words: Acute phase proteins; Biomarker; Lung; sTREM-1.
Inflammatory Airway Disease (IAD) includes clinicalentities characterized by cough, decreased perfor-
mance and delayed recovery after exercise, with lower
airway inflammation detected at bronchoalveolar lavage
fluid (BALF) cytology.1 As the bronchoalveolar lavage
is a procedure not routinely performed in the field, IAD
remains underdiagnosed. The identification of serum
biomarkers for lung inflammation would facilitate
disease recognition.
Biomarkers are “substances, structures or processes
that can be measured in the body or its products which
influence or predict the incidence of an outcome or dis-
ease”.2 Biomarkers of lung inflammation have been
studied, but few are pathognomonic for a given condi-
tion or specific for single organs. Both specific (surfac-
tant protein D, SP-D) and nonspecific (acute phase
proteins) inflammatory biomarkers are elevated in
blood of horses suffering from lower airway inflamma-
tory diseases (heaves and IAD). In heaves, circulating
haptoglobin concentrations are increased compared to
controls, with no overlapping measures between
groups.3 There is a significant increase in serum SP-D
concentrations in horses with IAD.4
We hypothesized that the protein expression of 4
biomarkers of pulmonary (SP-D) and nonspecific
inflammation haptoglobin, serum amyloid A, SAA and
the soluble form of triggering receptor expressed on
myeloid cells 1, sTREM-1, is higher in the serum of
horses with IAD. We aimed at investigating the concen-
trations of these biomarkers in the serum of horses with
IAD and controls, and at studying whether their distri-
bution pattern is associated with the inflammatory
phenotype detected at BALF cytology.
Material and Methods
Animals
Horses with IAD were selected among the cases referred to the
equine hospital of the Universite de Montreal for respiratory prob-
lems between September 2011 and 2013. The study was performed
in accordance with the guidelines of the Canadian Council on Ani-
mal Care and the protocol approved by the Ethics Committee of
the Universite de Montreal (#Rech-1647). Horses with IAD were
included in the study if they presented clinical signs of cough,
nasal discharge or increased breathing effort during/after exercise,
together with increased neutrophil (>5%), mast cell (>2%) or
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eosinophil (>1%) percentage at the BALF cytology.1 Control
horses were either selected among horses referred to the hospital
for nonrespiratory elective procedures and did not have signs of
diseases or inflammation detected at BALF cytology (n = 5), or
they were owned by the Universite de Montreal (n = 5). Exclusion
criteria for both groups of horses were the presence of systemic
inflammatory or infectious processes based on clinical examination
or results. Racehorses in training/racing were excluded, as were
horses with a history of increased respiratory effort at rest, or any
drug administration within the 15 days before admission. All the
client-owned horses were transported to the hospital on the day of
examination. The horses owned by the Universite de Montreal
were not trailered before sampling. All horses underwent complete
clinical and endoscopic examination of the respiratory system. All
owners signed an informed consent form to store samples for
research purposes.
Bronchoalveolar Lavage
Bronchoalveolar lavage procedure was performed as previously
described.5 Cytopreparations from unfiltered BALFa with Protocol
Hema 3b for differential counting of 400 cells.
Blood Collection
Blood was collected from the jugular veins by means of 18G
needles into sterile tubes. Ninety millilitres of blood were collected
from each horse. Within 2 hours from collection, plasma and
serum were harvested from the sample and 1.5 mL aliquots were
stored at -80°C until used. Serum samples were used for ELISA.
Protein Expression Studies
Surfactant protein D, SAA, haptoglobin and sTREM-1 were
quantified in serum samples using commercially available ELISA
kits. The cross-reactivity of the antibody used in the Surfactant
Protein D human Elisa kitc with the equine SP-D was validated by
the Western blot technique. The Phase Serum Amyloid A Mul-
tispecies Elisa,d the Equine Haptoglobulin Elisa,d and horse
TREM-1 Elisae were previously validated by the manufacturer and
used accordingly to the instructions. Plates were washed using an
automatic plate washerf and absorbance was obtained using a
microplate reader.g The assay standard curves ranged from 1.56 to
100 ng/mL for SP-D (serum dilution 1:10), 9.375 to 600 ng/mL
for haptoglobin (serum dilution 1:32000), 1.25–20 ng/mL for SAA
(serum dilution 1:2000) and 62.5 pg/mL-2000 pg/for sTREM.
When SAA concentrations exceeded the assay quantification
range, there were attributed the value 3.30 lg/mL (higher limit of
the linear part of the curve).
Statistics
Statistical analyses were performed with Prism 6.h All data were
analysed after Log10 transformation to reduce intergroup variabil-
ity. Normal distribution of data within each group was assessed
with Kolmogorov-Smirnov tests. Student t-tests or one-way
ANOVA with Tukey’s post-tests were used to compare the vari-
ables studied in different groups. Pearson tests were used for detect-
ing correlations between serum biomarker concentrations and
other variables assessed in serum or BALF in horses with IAD.
Results
Twelve horses with IAD and 10 controls were
included. The IAD group consisted of 4 Warmbloods, 5
Quarter-Horses and associated breeds, and 3 Draft
horses. Their average age was 6 years old (range 2–14).
There were 4 females, 6 geldings and 2 males. Horses
were performing light to moderate work. Disease dura-
tion was less than 2 years for most of them except one
(4-year duration). They were fed hay while being
stabled (8/12) or kept in paddock/pastures (4/12). The
control group consisted of 2 Draft horses, 1 Haflinger,
2 Quarter-horses and 5 Standardbreds that were part of
the University’s herd. Their average age was 6 years old
(range 2–9); there were 5 females, 4 geldings and 1
male. All control horses were performing light work,
and were stabled and fed hay.
All IAD horses had increased BALF neutrophil per-
centage (range 6–53%), 7 horses also had BALF masto-
cytosis (range 3–9%), 1 horse had BALF eosinophilia
(3%) and 1 horse had both BALF mastocytosis (3%)
and eosinophilia (3%). Control horses had normal
BALF neutrophil (range 1–3.5%) and mast cell percent-
age (<2%). Blood neutrophil (P = .3), leucocyte
(P = .4), and fibrinogen (P = .6) concentrations were
similar between the 2 groups of horses.
The concentrations of SP-D (P = .0001), haptoglobin
(P = .006) and SAA (P = .003), but not sTREM-1
(P = .87), were significantly increased in the sera of
horses with IAD (Fig 1). Data overlap between the 2
groups was minimal for serum SP-D concentrations.
Raw data ranged from 3.88 to 288 ng/mL for SP-D
(min-max: 3.88–21.98 in controls and 14.8–288 in IAD),
from 1.18 9 106 to 10.6 9 106 ng/mL for haptoglobin
(1.18 9 106–5.52 9 106 in controls and 2.59 9 106–
10.6 9 106 in IAD), from 0.69 to 36.14 ng/mL for
sTREM-1 (0.69–17.34 in controls and 1.56–36.14 in
IAD) and from 0.21 to 3.30 lg/mL for SAA (0.21–1.55
in controls and 0.28–3.30 in IAD). Serum samples from
4 horses with IAD had SAA concentrations exceeding
the assay quantification range. When combined, the
sum of the log-transformed values of SP-D and hap-
toglobin (P < .0001), of SP-D and sTREM-1
(P = .003), of SAA and SP-D (P < .0001), of SAA and
haptoglobin (P = .0001) and of SAA and sTREM-1
(P = .025), were significantly higher in the sera of
horses with IAD compared to controls. The sum of the
concentrations of haptoglobin and sTREM-1 was not
different between both groups (P = .24) (Fig 2C). No
overlap was observed between the 2 groups when the
sum of SP-D and haptoglobin concentrations was stud-
ied (Fig 2A). A cut-off point of 7.70 (Log-transformed
value) allowed complete distinction of horses with IAD
from controls. A cut-off value of 0.80 for the sum of
SAA and SP-D (Fig 2D) permitted differentiation of
horses with IAD from controls (sensitivity = 100%,
specificity = 90%). In horses with IAD, SAA concentra-
tion was significantly correlated with neutrophil per-
centage in BALF (r = 0.56, P = .05). The two horses
with BALF eosinophil percentage >1% had the highest
serum concentrations of SP-D. Haptoglobin values were
negatively correlated with serum neutrophil concentra-
tions (r = 0.69, P = .01), neutrophil percentage in
BALF (r = 0.75, P = .005) and with serum leucocyte
concentrations (r = 0.61, P = .04). Haptoglobin
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concentrations were significantly affected by the pres-
ence of haemosiderophages (P = .0009) in BALF.
Horses with haemosiderophages detected at BALF
cytology (there were no haemosiderophages found in
the BALF of the control group (Fig 3) had higher val-
ues of haptoglobin concentration in the serum com-
pared to the IAD-affected horses with no
haaemosiderophages and to the controls (P < .05 and
P < .001 respectively, Fig 3).
Discussion
Inflammatory Airway Disease is highly prevalent in
the equine population. However, diagnosis remains a
challenge, as clinical signs are not pathognomonic. The
implementation of biomarkers specific for lung inflam-
mation could facilitate its diagnosis. Our results demon-
strate that the serum concentrations of SP-D,
haptoglobin and SAA are increased in horses with IAD
compared to controls, moreover when combined, the
serum concentrations of SP-D and haptoglobin allow
differentiating horses with IAD from healthy horses
with no overlap between groups.
Surfactant protein D is a collectin mainly synthesized
in the lungs by alveolar type II cells. It plays an impor-
tant role in protecting the lungs against various inflam-
matory processes, allergies and infections. In our study,
and in agreement with a previous report,4 horses with
Fig 1. Serum concentration of SP-D (A), haptoglobin (B), sTREM-1 (C) and SAA (D) in horses with IAD and controls. Values were log
transformed for analysis.
Fig 2. Serum concentration of combined SP-D and haptoglobin (A), SP-D and sTREM-1 (B), haptoglobin and sTREM-1 (C), SAA and
SP-D (D), SAA and haptoglobin (E), and sTREM-1, and SAA (F) in horses with IAD and controls. Values were log transformed for anal-
ysis.
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IAD had higher serum concentrations of SP-D. Despite
SP-D being also expressed in the synovial fluid, diseases
of these organ systems tend to lower circulating SP-D
levels in man,6 whereas increases in serum SP-D con-
centrations have been associated to lung pathologies.4
Whether serum SP-D concentration also decreases in
horses with joint diseases has not been studied to date,
and would require investigation.
Serum amyloid A is a major acute phase protein
reported to range from <0.5 to 20 lg/mL. Serum SAA
levels are low in healthy individuals, and increase from
10 to 1000 times within a few hours from tissue injury,
to reach peak values within 24–28 h.7 Serum amyloid A
has immunoregulatory functions, linked to the develop-
ment of chronic diseases. In this study, and in agree-
ment with findings in heaves,3 serum SAA
concentrations had a 3.5-fold increase in horses with
IAD when compared to controls. As SAA increases are
proportional to the extent of tissue damage,7 it indicates
that horses with IAD sustain lung injuries of similar
magnitude to those found in heaves. Serum amyloid A
increases after transportation.8 In our study, horses
with IAD and 5 of the control horses underwent trans-
portation. The SAA values of control horses, whether
transported or not, were not significantly different
(Mann–Whitney t-test, P = .8), suggesting that trailer-
ing unlikely affected our results.
Circulating haptoglobin concentrations increase 1–10
times in the 12–24 h after an injury, and peaks 72 h
later.7 Haptoglobin is mainly produced to scavenge hae-
moglobin. In our study, haptoglobin was increased on
average 2-fold in horses with IAD, whereas its serum
concentration has been reported to increase 5–10-fold
after inflammation and infection in horses.7 Serum hap-
toglobin was increased in 3/4 horses with IAD present-
ing haemosiderophages in their BALF, whereas horses
with IAD with no haemosiderophages have a concentra-
tion of serum haptoglobin similar to the controls. These
findings suggest that the specificity of serum haptoglobin
as biomarkers for IAD should be ascertained in the pres-
ence of exercise-induced pulmonary haemorrhage. It has
been hypothesized that peripheral blood and airway neu-
trophil degranulation may constitute a source of hap-
toglobin in horses with inflammatory lung diseases such
as heaves.3 The negative correlations we observed
between haptoglobin serum concentrations and both
blood and BALF neutrophils would not support this
hypothesis, and was unexpected. Haemosiderophages
may have a less potent neutrophil chemo-attractive
activity than other inflammatory cells, but more studies
are needed to corroborate this assumption.
Comparing results from this study to a previous
report,3 horses with IAD have higher haptoglobin values
than those of heave-affected horses, which would support
the hypothesis of disease progression from IAD to
heaves. However, a study evaluating both diseases in the
same conditions is needed to confirm that hypothesis.
The TREM-1 is a membrane receptor expressed on
blood neutrophils and monocytes, and also on alveolar
macrophages, which has a role in lung inflammatory
response against infections by amplifying the TLR-asso-
ciated response.9 As IAD is clinically comparable to
mild to moderate human asthma, not surprisingly
sTREM-1 serum concentrations were similar between
horses with IAD and controls.
Conclusions
Measuring several inflammation-related blood pro-
teins increases their sensitivity as blood biomarkers for
the diagnosis of IAD. The combination of an organ-
specific biomarker (SP-D) and of an acute phase protein
(haptoglobin) yielded the best diagnostic results. How-
ever, the effect of other causes of reduced performances
in horses, whether affecting the lungs or other organs
on SP-D is still unknown, even though our group
recently reported no difference in SAA and haptoglobin
concentrations in blood of racehorses with and without
IAD.10 Also, as healthy horses were studied as controls,
the effect of other pulmonary conditions on acute phase
proteins could represent a potential source of bias (de-
creasing sensitivity and specificity of the test). Prospec-
tive studies investigating these aspects are needed before
these biomarkers can be employed as a diagnostic tool
in the field.
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